We evaluated the in vitro activity of fluconazole, itraconazole, ketoconazole, 5-fluorocytosine and amphotericin B against 30 clinical isolates of Saccharomyces cerevisiae by a broth microdilution method, following the NCCLS recommendation. Testing was performed either in RPMI-1640 or yeast nitrogen base (YNB). YNB supported the growth of all isolates tested, while results in RPMI-1640 were not obtained for six isolates (20%). The MIC of all three azoles in YNB were one or two dilutions higher than those obtained in RPMI-1640 (P=0·0001 for fluconazole and itraconazole, P=0·03 for ketoconazole). Elevated MICs were observed for all three azoles, while all the isolates were susceptible to 5-fluorocytosine and amphotericin B.
Introduction
that S. cerevisiae was the most commonly isolated yeast after Candida albicans and C. glabrata [4] . In addition, Saccharomyces cerevisiae is a yeast used in baking, it has been reported that some virulence characteristics, brewing, viniculture and for genetic and molecular such as the ability to grow in suboptimal temperatures, biology research. Although commonly considered a formation of pseudohyphae, frequency of morphology non-pathogen, it has been reported recently in a number switching and increased pathogenicity in mouse inof cases of sepsis in patients with predisposing factors fection models, are more pronounced in clinical than such as prolonged hospitalization, immunosuppression, in laboratory isolates of S. cerevsiae [5] [6] [7] . broad-spectrum antibiotic therapy and foreign devices Thus far, an optimal treatment for infections due such as central venous catheters or prosthetic cardiac to S. cerevisiae has not been established and little valves [1] [2] [3] were prepared in water (fluconazole and 5-fluorocytosine), polyethylene glycol (itraconazole and ketoconazole) or dimethyl sulphoxide (amphotericin B). Susceptibility testing was performed by a broth microdilution method, following the NCCLS recommendations [10] . Since in pilot experiments we found that RPMI-1640 did not support the growth of some isolates of S. cerevisiae, we conducted all the experiments by using either RPMI-1640 medium (Gibco) buffered to pH 7·0 with 0·165  morpholinepropanesulphonic acid (MOPS) buffer (Sigma) and yeast-nitrogen-base (YNB) medium (YNB 6·7 g, glucose 10 g, asparagine 1·5 g 100 −1 ml, Difco) buffered to pH 7·0 with 0·165  MOPS. Fifty l of the inoculum, prepared spectrophotometrically and further diluted in test medium to obtain a concentration ranging from 1·0 to 5·0 × 10 3 cfu ml −1 (2×inoculum), were added into the wells of each row of the microplates bringing the drug dilutions to the final test concentrations: 0·125-64 mg l −1 for fluconazole and 5-fluorocytosine, 0·03-16 mg l −1 for ketoconazole and amphotericin B and 0·0078-4·0 mg l −1 for itraconazole. The microplates were incubated at 35°C and read at 48 h. Visual reading (V) was performed with the aid of a reading mirror; the growth in each well was compared with that in the growth control (drug-free) well. Azole and 5-fluorocytosine MIC were defined as the lowest concentrations at which a prominent decrease in turbidity was observed (MIC-2; turbidity in the well which corresponds to 50% less than that in the control well [10]), while amphotericin B MIC was defined as the lowest MR 700) set at 490 nm after the microplates had been agitated for 5 min by an automatic plate shaker. SP MIC endpoints were determined as the first concentration of
Materials and methods
the antifungal agent at which turbidity in the well was 50% (azoles and 5-fluorocytosine) or 90% less Thirty recent clinical isolates of S. cerevisiae were used (amphotericin B) than that in the control well. The MIC in the study. They were obtained from 25 individuals: data were logarithmically transformed to approximate a 16 AIDS patients and nine HIV-negative subjects. The normal distribution prior to statistical analysis. Constrains were isolated from faeces (n=8), oral cavity tinuous variables were compared with the Mann-(n=6), blood (n=5), vagina (n=5), sputum (n=4) and Whitney test. Differences were considered significant if skin (n=1). Putative identification of each isolate to P was less than 0·05. the species level was carried out by morphological and Molecular typing of selected isolates was acbiochemical conventional methods. C. krusei ATCC complished by electrophoretic karyotyping (EK). 6258 and S. cerevisiae ATCC 9763 were used as control Briefly, agarose plugs containing yeast DNAs were organisms in all experiments. prepared as described previously and inserted in 1% The following five antifungal agents were used: fluagarose gel [11] (Ultra Pure DNA Grade Agarose; Bioconazole (Pfizer), itraconazole (Janssen), ketoconazole Rad). Chromosomes were resolved with a counter-(Janssen), amphotericin B (E. R. Squibb & Sons) and 5-fluorocytosine (Hoffmann-La Roche). Stock solutions clamped homogeneous electric-field system (CHEF-DR 
a V, visual reading; SP, spectrophotometric reading; b 50% and 90%, MIC at which 50% and 90% of the isolates tested were inhibited.
II, Bio-Rad). Electrophoresis was carried out at 6 V 0·26); ketoconazole MIC ranged from 0·06 to 0·5 mg l
and from 0·03-1·0 mg l −1 for the strains isolated from and 14°C for 24 h with switch time ramping from 60 to 120 s. S. cerevisiae (Bio-Rad) was used as DNA size the HIV-negative and -positive individuals, respectively (P=0·84). Similarly, no differences between the two standard. Gels were stained with ethidium bromide and photographed under UV light.
groups were found for azoles MIC obtained in YNB (data not shown). All the isolates were susceptible in vitro to 5-fluorocytosine and to amphotericin B (Table 1) . MICs for all five antifungal agents were confirmed by the spectrophotometric reading (Table 1) . While YNB supported the growth of all isolates tested, results in RPMI-1640 were not obtained for six isolates Six strains of S. cerevisiae isolated from the faeces and from consecutive blood-cultures of an AIDS patient (20%) because of poor growth in this test medium. The MIC of all three azoles obtained in YNB were over a 7-month period were typed by EK (Fig. 1) . The first strain was isolated from the faeces in June 1995 constantly one or two dilutions higher than those obtained in RPMI-1640 (P=0·0001 for fluconazole and (fluconazole MIC: 16 mg l −1
Results and Discussion
), four other strains were isolated from four blood cultures obtained on 17 Janitraconazole; P=0·03 for ketoconazole), while no differences were found for 5-fluorocytosine and amuary 1996 (range fluconazole MIC: 4·0-8·0 mg l −1
), while the last strain was isolated from a blood culture photericin B MICs. Elevated MIC were observed for all three azoles. Fluconazole MIC at which 90% of the obtained on 18 January 1996 (fluconazole MIC:
). EK showed the maintenance of the same strains were inhibited (MIC 90 ) were 4·0 mg l −1 in RPMI-1640 and 8·0 mg l −1 in YNB; itraconazole MIC 90 were DNA type over time (Fig. 1) 
